Clinical and microbiological characterization of carbapenem-resistant Acinetobacter baumannii bloodstream infections

Journal of Medical Microbiology

Volumn 60, Issue 5, 2011, Pages 605-611

  Song, Joon Young ^a   Cheong, Hee Jin ^a   Choi, Won Suk ^a   Heo, Jung Yeon ^a   Noh, Ji Yun ^a   Kim, Woo Joo ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEM; CARBAPENEMASE; CEFTIZOXIME; CIPROFLOXACIN; COLISTIN; IMIPENEM; MEROPENEM; RIFAMPICIN; TIGECYCLINE;

ABDOMINAL INFECTION; ACINETOBACTER INFECTION; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL PNEUMONIA; BLOODSTREAM INFECTION; CATHETER INFECTION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; LUNG; MALE; MEDICAL RECORD REVIEW; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURGICAL INFECTION; URINARY TRACT INFECTION;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADULT; AGED; ANIMALS; BACTEREMIA; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CARBAPENEMS; DISEASE MODELS, ANIMAL; FEMALE; GENES, BACTERIAL; HUMANS; MALE; MICE; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PNEUMONIA, BACTERIAL; REPUBLIC OF KOREA; RIFAMPIN; RISK FACTORS;

EID: 79955655452     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.029439-0     Document Type: Article

References (28)

1. Aoki, N., Tateda, K., Kikuchi, Y., Kimura, S., Miyazaki, C., Ishii, Y., Tanabe, Y., Gejyo, F. &Yamaguchi, K. (2009). Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. J Antimicrob Chemother 63, 534-542.
2. Bergogne-Bérézin, E. & Towner, K. J. (1996). Acinetobacter spp. As nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev 9, 148-165.
3. Bernabeu-Wittel, M., García-Curiel, A., Pichardo, C., Pachón-Ibáñ ez, M. E., Jiménez-Mejías, M. E. and Pachón, J. (2004). Morphological changes induced by imipenem and meropenem at sub-inhibitory concentrations in Acinetobacter baumannii. Clin Microbiol Infect 10, 931-934.
4. Corvec, S., Poirel, L., Naas, T., Drugeon, H. & Nordmann, P. (2007). Genetics and expression of the carbapenem-hydrolyzing oxacillinase gene blaOXA-23 in Acinetobacter baumannii. Antimicrob Agents Chemother 51, 1530-1533.
5. Erbay, A., Idil, A., Gö zel, M. G., Mumcuog ̌ lu, I. & Balaban, N. (2009). Impact of early appropriate antimicrobial therapy on survival in Acinetobacter baumannii bloodstream infections. Int J Antimicrob Agents 34, 575-579.
6. Giamarellos-Bourboulis, E. J., Xirouchaki, E. & Giamarellou, H. (2001). Interactions of colistin and rifampin on multidrugresistant Acinetobacter baumannii. Diagn Microbiol Infect Dis 40, 117-120.
7. Glew, R. H., Moellering, R. C., Jr & Kunz, L. J. (1977). Infections with Acinetobacter calcoaceticus (Herellea vaginicola): clinical and laboratory studies. Medicine (Baltimore) 56, 79-97.
8. Héritier, C., Poirel, L. & Nordmann, P. (2006). Cephalosporinase overexpression resulting from insertion of ISAba1 in Acinetobacter baumannii. Clin Microbiol Infect 12, 123-130.
9. Kwon, K. T., Oh, W. S., Song, J. H., Chang, H. H., Jung, S. I., Kim, S. W., Ryu, S. Y., Heo, S. T., Jung, D. S. & other authors (2007). Impact of mipenem resistance on mortality in patients with Acinetobacter acteraemia. J Antimicrob Chemother 59, 525-530.
10. Lee, K., Chong, Y., Shin, H. B., Kim, Y. A., Yong, D. & Yum, J. H. 2001). Modified Hodge and EDTA-disk synergy tests to screen etallo-b-lactamase-producing strains of Pseudomonas and cinetobacter species. Clin Microbiol Infect 7, 88-91.
11. Lee, S. O., Kim, E. S., Kim, H. Y., Park, E. S., Jin, H. Y., Ki, H. K., Choi,. J., Jeong, S. Y., Kim, S. R. & other authors (2008). [Korean osocomial infections surveillance system, intensive care unit module report: data summary from July 2007 through June 2008]. Korean J Nosocomial Infect Control 13, 69-82 (in Korean).
12. Li, J., Nation, R. L., Owen, R. J., Wong, S., Spelman, D. &Franklin, C. 2007). Antibiograms of multidrug-resistant clinical Acinetobacter aumannii: promising therapeutic options for treatment of infection ith colistin-resistant strains. Clin Infect Dis 45, 594-598.
13. Maragakis, L. L. & Perl, T. M. (2008). Acinetobacter baumannii: Epidemiology, antimicrobial resistance, and treatment options. Clin infect Dis 46, 1254-1263.
14. Metan, G., Sariguzel, F. & Sumerkan, B. (2009). Factors influencing survival in patients with multi-drug-resistant Acinetobacter bacteraemia. Eur J Intern Med 20, 540-544.
15. unoz-Price, L. S. & Weinstein, R. A. (2008). Acinetobacter infection. Engl J Med 358, 1271-1281.
16. Pachón-Ibáñez, M. E., Fernández-Cuenca, F., Docobo-Pé rez, F., achó n, J. &Pascual, A. (2006). Prevention of rifampicin resistance n Acinetobacter baumannii in an experimental pneumonia murine model, using rifampicin associated with imipenem or sulbactam. J Antimicrob Chemother 58, 689-692.
17. Pankey, G. A. (2005). Tigecycline. J Antimicrob Chemother 56, 470-480.
18. Peleg, A. Y., Seifert, H. & Paterson, D. L. (2008). Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 1, 538-582.
19. OXA-58 in Acinetobacter baumannii. Antimicrob Agents Chemother 50, 1442-1448.
20. Poutanen, S. M., Louie, M. & Simor, A. E. (1997). Risk factors, clinical features and outcome of Acinetobacter bacteremia in adults. Eur J Clin Microbiol Infect Dis 16, 737-740.
21. Saballs, M., Pujol, M., Tubau, F., Peña, C., Montero, A., Domínguez, M. A., Gudiol, F. and Ariza, J. (2006). Rifampicin/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections. J Antimicrob Chemother 58, 697-700.
22. Seifert, H., Strate, A. & Pulverer, G. (1995). Nosocomial bacteremia due to Acinetobacter baumannii: clinical features, epidemiology, and predictors of mortality. Medicine (Baltimore) 74, 340-349.
23. Song, J. Y., Kee, S. Y., Hwang, I. S., Seo, Y. B., Jeong, H. W., Kim, W. J. & Cheong, H. J. (2007). In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother 60, 317-322.
24. Song, J. Y., Lee, J., Heo, J. Y., Noh, J. Y., Kim, W. J., Cheong, H. J. & Hwang, I. S. (2008). Colistin and rifampicin combination in the treatment of ventilator-associated pneumonia caused by carbapenemresistant Acinetobacter baumannii. Int J Antimicrob Agents 32, 281- 284.
25. Song, J. Y., Cheong, H. J., Lee, J., Sung, A. K. & Kim, W. J. (2009). Efficacy of monotherapy and combined antibiotic therapy for carbapenem-resistant Acinetobacter baumannii pneumonia in an immunosuppressed mouse model. Int J Antimicrob Agents 33, 33-39.
26. Turton, J. F., Ward, M. E., Woodford, N., Kaufmann, M. E., Pike, R., Livermore, D. M. & Pitt, T. L. (2006). The role of ISAba1 in expression of OXA carbapenemase genes in Acinetobacter baumannii. FEMS Microbiol Lett 258, 72-77.
27. Wareham, D. W., Bean, D. C., Khanna, P., Hennessy, E. M., Krahe, D., Ely, A. & Millar, M. (2008). Bloodstream infection due to Acinetobacter spp: epidemiology, risk factors and impact of multi-drug resistance. Eur J Clin Microbiol Infect Dis 27, 607-612.
28. CLSI (2006). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, approved standard, 7th edn, M7-A7. Wayne, PA: Clinical and Laboratory Standards Institute.